| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2082916 | Drug Discovery Today: Therapeutic Strategies | 2010 | 6 Pages |
Abstract
Immunotherapy for prostate cancer became a therapeutic option for metastatic castration-resistant prostate cancer after a phase III trial of sipuleucel-T demonstrated an overall survival advantage relative to placebo. A similar phase II trial in the same population but with the vaccine PSA-TRICOM also demonstrated an overall survival advantage. As these and similar immunotherapeutic options for prostate cancer emerge, it becomes important to understand their unique characteristics and potential benefits.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
Christopher R. Heery, Ravi A. Madan,